ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
-4.03%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$307M
AUM Growth
+$44.9M
(+17%)
Cap. Flow
+$58.1M
Cap. Flow
% of AUM
18.91%
Top 10 Holdings %
Top 10 Hldgs %
56.38%
Holding
70
New
21
Increased
13
Reduced
13
Closed
19
Top Buys
| 1 |
Takeda Pharmaceutical
TAK
|
$14.3M |
| 2 |
Labcorp
LH
|
$12.8M |
| 3 |
Eli Lilly
LLY
|
$12.4M |
| 4 |
Bristol-Myers Squibb
BMY
|
$11.3M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
$10.1M |
Top Sells
| 1 |
Boston Scientific
BSX
|
$15.6M |
| 2 |
Hologic
HOLX
|
$8.85M |
| 3 |
Avantor
AVTR
|
$7.35M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$5.82M |
| 5 |
Centene
CNC
|
$5.78M |
Sector Composition
| 1 | Healthcare | 77.14% |
| 2 | Real Estate | 4.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Merit Medical Systems
MMSI
$5.34B
| $2.89M | 0.94% |
51,218
+30,995
| +153% | +$1.75M |
|
27
Arcus Biosciences
RCUS
$1.24B
| $2.55M | 0.83% |
97,327
+32,571
| +50% | +$852K |
|
28
Insmed
INSM
$30.3B
| $2.32M | 0.76% |
107,713
-34,358
| -24% | -$740K |
|
29
Galapagos
GLPG
$2.06B
| $2.17M | 0.71% |
50,822
-588
| -1% | -$25.1K |
|
|
ADAP
30
Adaptimmune Therapeutics
ADAP
$13.9M
| $1.92M | 0.63% |
1,788,517
-35,548
| -2% | -$38.2K |
|
|
CANO
31
DELISTED
Cano Health, Inc.
CANO
| $1.83M | 0.6% |
+2,109
| New | +$1.83M |
|
32
Veracyte
VCYT
$2.41B
| $1.81M | 0.59% |
+108,751
| New | +$1.81M |
|
|
33
Avantor
AVTR
$8.74B
| $1.49M | 0.48% |
75,948
-374,873
| -83% | -$7.35M |
|
34
Sutro Biopharma
STRO
$85.6M
| $1.48M | 0.48% |
266,679
-90,786
| -25% | -$504K |
|
35
Teva Pharmaceuticals
TEVA
$21.5B
| $1.45M | 0.47% |
179,226
-280,603
| -61% | -$2.26M |
|
36
Option Care Health
OPCH
$4.7B
| $1.37M | 0.45% |
+43,457
| New | +$1.37M |
|
37
Owens & Minor
OMI
$423M
| $1.35M | 0.44% |
+55,914
| New | +$1.35M |
|
38
Vaxcyte
PCVX
$4.17B
| $1.26M | 0.41% |
+52,309
| New | +$1.26M |
|
|
RETA
39
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $612K | 0.2% |
+24,352
| New | +$612K |
|
40
Maravai LifeSciences
MRVI
$341M
| $580K | 0.19% |
22,709
-306
| -1% | -$7.82K |
|
41
Acumen Pharmaceuticals
ABOS
$82.4M
| $555K | 0.18% |
+55,328
| New | +$555K |
|
|
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $553K | 0.18% |
+7,915
| New | +$553K |
|
43
Relmada Therapeutics
RLMD
$48.8M
| $524K | 0.17% |
+14,145
| New | +$524K |
|
44
Cytokinetics
CYTK
$5.98B
| $446K | 0.15% |
9,211
-2,327
| -20% | -$113K |
|
|
MOR
45
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $344K | 0.11% |
+68,290
| New | +$344K |
|
46
Biodesix
BDSX
$61.9M
| $165K | 0.05% |
130,136
-617
| -0.5% | -$782 |
|
|
ATNX
47
DELISTED
Athenex, Inc. Common Stock
ATNX
| $142K | 0.05% |
+26,333
| New | +$142K |
|
48
Praxis Precision Medicines
PRAX
$980M
| – | – |
-5,273
| Closed | -$194K |
|
49
Acadia Healthcare
ACHC
$2.15B
| – | – |
-16,189
| Closed | -$1.1M |
|
50
ADC Therapeutics
ADCT
$370M
| – | – |
-58,967
| Closed | -$469K |
|